Jabil Healthcare Announces the Launch of the Qfinity™ Autoinjector Platform, a Reusable Drug Delivery Device with Broad Applicability
18.5.2022 15:30:00 EEST | Business Wire | Press release
Jabil Healthcare, a division of Jabil Inc. (NYSE: JBL), announces the launch of the Qfinity™ autoinjector platform, a simple, reusable and modular solution for subcutaneous (SC) drug self-administration, at a lower cost than market alternatives — supporting the emerging prioritization of sustainable drug delivery within the pharmaceutical industry.
Jabil Healthcare has been a trusted partner with the world’s leading healthcare brands for over 30 years, and now the company is excited to offer the Qfinity autoinjector platform, designed to help patients self-administer a variety of injectables, including larger volume, higher viscosity medicines. This represents the first time Jabil Healthcare Pharmaceutical Delivery Systems will directly offer a drug delivery device platform.
“The Qfinity autoinjector platform is versatile with broad technical specifications for drug volumes and drug viscosities. It features a patient-centric form factor at up to 65% lower cost per injection than market-leading disposable autoinjectors,” said Oliver Eden, Business Unit Director, Jabil Healthcare. “Our product is intentionally designed to be sustainable and reusable at the core, all while being delivered at a lower cost than market alternatives.”
Medical waste is widely recognized as a challenge for the industry and the environment. A 2019 material study found that the highest percentage of medical-grade plastic waste is generated by plastic disposable syringes.1 To address this problem, the durable Qfinity autoinjector handles over 100 injections per device and accommodates 1 mL or 2.25 mL pre-filled disposable cassettes. Due largely to the fact that fewer components and material are consumed, it is estimated that the Qfinity autoinjector platform delivers up to a 65% reduction in cost per injection versus the market-leading disposable autoinjectors, as well as up to 60% reduction in carbon footprint per injection, 50% smaller manufacturing footprint and a 70% reduction in CAPEX. 2
The attractive handheld device is also available in a connected version, the Qfinity+ autoinjector, which enables medical teams to remotely monitor their patients’ care and compliance via built-in sensors and electronics — without any added complexity. The drive unit form factor and the user steps are exactly the same as the non-connected version. Capture and transmission of data operates seamlessly by virtue of the Qfinity+ Home Hub solution, which provides charging and seamless cellular data transfer functionality in near real-time without requiring input from the patient.3
“Qfinity+ enables connectivity without impacting ease of use, while enabling seamless data transfer at up to 20% lower cost per injection compared to unconnected, market-leading disposable autoinjectors. Within the disposable mechanical autoinjector market, a common route for delivering connectivity is a 'sleeve' that fits over the autoinjector and captures adherence and/or compliance and communicates those events to the user’s smartphone via Bluetooth. Jabil’s decision to instead develop the cellular Qfinity+ Home Hub solution goes back to our primary objective: maximizing access,” said Conor Mulcahy, Senior Director of Strategic Projects, Jabil.
The Qfinity autoinjector platform comes to market as one of the most versatile autoinjector solutions available today. It is sustainable, accessible and inclusive – both in ease of use and the seamless connectivity option it provides to address the new digital health environment.
“Pharma manufacturers have a significant opportunity to influence how the healthcare ecosystem evolves in solving today’s challenges with tomorrow’s solution. The way forward is to make life easier for patients, provide better tools for improving health and reduce medical waste,” said Eden.
1. “The Management and Stewardship of Medical Plastic Waste using Raman Spectroscopy to Sustain Circular Economy” ©2019 E-Health and Bioengineering, Ioana Marica, Mihaela Aluas, Simona Cinta Pinzaru, Babes-Bolyai University
2. Based on 100k patients per annum with weekly dosing vs. market-leading autoinjectors. Cost reduction will vary depending on dosage, frequency and patient pool.
3. Requires access to a cellular network, does not require wifi or smart phone.
About Jabil:
Jabil (NYSE: JBL) is a manufacturing solutions provider with over 260,000 employees across 100 locations in 30 countries. The world's leading brands rely on Jabil's unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights and global product management expertise. Driven by a common purpose, Jabil and its people are committed to making a positive impact on their local community and the environment. Visit www.jabil.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005312/en/
Contact information
Michelle Saro
Senior Director of Marketing, Jabil
1.206.272.0813
Michelle_Saro@jabil.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom